Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
TFOS is indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated
